Evonik to expand production capacity for isobutene derivatives by more than 50% from site in Marl, Germany; isobutene specialties face high demand as intermediates used in pharmaceutical and chemical industries, company says

Sample article from our Health Care Sector

MARL, Germany , March 30, 2022 (press release) –

 

Evonik has invested a double-digit million euro sum to increase production capacity for isobutene derivatives at its Marl location.

  • Production capacity for isobutene derivatives increases by more than 50 percent
  • Double-digit million euro investment for expansion of C4 production network
  • Expansion improves security of supply, flexibility and product quality

Evonik has invested a double-digit million euro sum to increase production capacity for isobutene derivatives at its Marl location. The isobutene part of the C4 production network produces the petrochemical specialties Tertiary Butanol (TBA), Di-isobutene (DiB) and 3,5,5-Trimethylhexanal (TMH). The expansion, which was recently completed, increases capacity for isobutene derivatives by more than 50 percent. In addition, the expansion improves security of supply, flexibility and product quality for the customers.

Evonik's isobutene specialties are already in high demand as intermediates for the pharmaceutical and chemical industries. "As a leading European key supplier of high-purity isobutene derivatives, we willingly rise to the challenge of supporting our customers' dynamic growth and continuing to invest in product quality and security of supply," says Dr. Hinnerk Gordon Becker, head of the Specialties market segment at Evonik Performance Intermediates. "That's why, in June 2020, we already began the targeted expansion of our C4 Verbund and to eliminate existing bottlenecks in production and logistics. In this way, we are further expanding our position in the field of high-purity isobutene derivatives and also living up to our leadership role," Becker continues.

The conversion work has increased the purity of the 3,5,5-Trimethylhexanal produced in Marl from around 88 to more than 95 percent. Customers will benefit from this: In future, they will be able to use the isobutene derivative directly in their own production process without having to purify it first.

Along with the capacity expansion, the business line is also optimizing logistics to meet customer needs even better. "In the course of the expansion, we have taken extensive measures to significantly increase both production and delivery flexibility. We are currently also working on optimally serving highly specialized customer industries with smaller requirements, such as those in the field of flavors and fragrances. This opens up completely new applications for our petrochemical specialties," Becker continues.

 

Background information on the products:

Tertiary Butanol is available from Evonik in two grades: pure, or as an azeotropic mixture. It is used to produce organic peroxides for the plastics industry and special solvents and tablet coatings for the pharmaceutical industry.

Di-isobutene is a highly branched C8 molecule. It is an important intermediate used to produce UV stabilizers, high performance lubricants and special polymer resins.

3,5,5-Trimethylhexanal is an aldehyde with high isomeric purity. The intermediate is used to produce high-performance lubricants (especially cooling lubricants) and lubricant additives, as well as specialty products for the cosmetics and fragrances industries.

Please note when using the press photos:

Images may only be used in conjunction with the press release.

COMPANY INFORMATION
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

ABOUT PERFORMANCE MATERIALS
The forever young classics of the Performance Materials Division stand for products and technologies that are continuously improved. They are the basis for many modern applications, for example in the areas of mobility, nutrition, pharmaceuticals or plastics. The divisions portfolio generated sales of €2.91 billion in 2021 with about 1,600 employees.

DISCLAIMER
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Health Care Sector Coverage
See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.